Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.87 |
| ▸ | MEN1 | O00255 | 8/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.87 |
| ▸ | THRB | P10828 | 7/20 | 0.87 |
| ▸ | BLM | P54132 | 7/20 | 0.87 |
| ▸ | RECQL | P46063 | 6/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.87 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.87 |
| ▸ | MAPT | P10636 | 5/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.87 |
| ▸ | STAT6 | P42226 | 4/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.87 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.87 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.87 |
| ▸ | HTT | P42858 | 3/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL23909357 | 1.00 | MEN1 (0.87) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL14953344 | 0.99 | MEN1 (0.87) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL19024333 | 0.97 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| Daunorubicin SCHEMBL29354629 | 0.94 | MEN1 (0.85) | MEN1KMT2ATHRBBLMRECQL | |
| Daunorubicin SCHEMBL42311 | 0.94 | MEN1 (0.85) | MEN1KMT2ATHRBBLMRECQL | |
| Daunorubicin SCHEMBL22534202 | 0.93 | MEN1 (0.85) | MEN1KMT2ATHRBBLMRECQL | |
| Daunorubicin SCHEMBL3644783 | 0.93 | MEN1 (0.85) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21914951 | 0.93 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22403027 | 0.93 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL23365786 | 0.93 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| EP-4135686-A1 | BASIC CHEMOTHERAPEUTIC INTRATUMOUR INJECTION FORMULATION | US Nano Food & Drug Inc (US) | 2023-02-22 | — | — | EP | claimed |
| CN-114929213-A | Alkaline chemotherapeutic intratumoral injection composition | 美国纳米食品药品公司 | 2022-08-19 | — | — | CN | claimed |
| WO-2021211294-A1 | BASIC CHEMOTHERAPEUTIC INTRATUMOUR INJECTION FORMULATION | US Nano Food & Drug INC (US) | 2021-10-21 | — | — | WO | claimed |
| US-20210315913-A1 | BASIC CHEMOTHERAPEUTIC INTRATUMOUR INJECTION FORMULATION | US Nano Food & Drug, Inc (US) | 2021-10-14 | — | — | US | claimed |
| CN-105919952-A | Triptorelin doxorubicin freeze-drying composition and preparation method thereof | 国药心制药有限公司 | 2016-09-07 | — | — | CN | claimed |
| EP-2787977-A1 | LIPOSOMAL DRUG ENCAPSULATION | The Regents of The University of California (US) | 2014-10-15 | — | — | EP | claimed |
| WO-2013086526-A1 | LIPOSOMAL DRUG ENCAPSULATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | WO | claimed |
| US-20260146064-A1 | PH-SENSITIVE MEMBRANE DISRUPTIVE PEPTIDES AND USE THEREOF | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2026-05-28 | — | — | US | disclosed |
| EP-4696326-A1 | PIKFYVE PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2026-02-18 | — | — | EP | disclosed |
| CN-116003400-B | 2-Formyl tetrahydronaphthyridine compound and medicinal composition and application thereof | 暨南大学 | 2025-05-02 | — | — | CN | disclosed |
| CN-116375994-B | PH-sensitive membrane-broken polyester and application thereof | 华南理工大学 | 2025-05-02 | — | — | CN | disclosed |
| CN-116848094-B | Tertiary amine lipid compounds and uses thereof | 华南理工大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-116063283-B | 3-Amino indazole compound and application thereof | 暨南大学 | 2025-03-25 | — | — | CN | disclosed |
| EP-0394314-B2 | MULTIPLE STEP ENTRAPMENT/LOADING PROCEDURE FOR PREPARING LIPOPHILIC DRUG-CONTAINING LIPOSOMES | VESTAR INC (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0394314-B1 | MULTIPLE STEP ENTRAPMENT/LOADING PROCEDURE FOR PREPARING LIPOPHILIC DRUG-CONTAINING LIPOSOMES | VESTAR, INC. (US) | 1993-03-03 | — | — | EP | disclosed |
| EP-0394314-A4 | MULTIPLE STEP ENTRAPMENT/LOADING PROCEDURE FOR PREPARING LIPOPHILIC DRUG-CONTAINING LIPOSOMES | — | 1991-01-09 | — | — | EP | disclosed |
| EP-0394314-A1 | MULTIPLE STEP ENTRAPMENT/LOADING PROCEDURE FOR PREPARING LIPOPHILIC DRUG-CONTAINING LIPOSOMES. | VESTAR INC (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4946683-A | USING PHOSPHOLIPID, ACID, AND BASE; DRUG DELIVERY | VESTAR, INC. (US) | 1990-08-07 | — | — | US | disclosed |
| WO-1989004656-A1 | MULTIPLE STEP ENTRAPMENT/LOADING PROCEDURE FOR PREPARING LIPOPHILIC DRUG-CONTAINING LIPOSOMES | VESTAR, INC. (US) | 1989-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | STAT3, JAK2, JAK1 | TOP2A 2400/4885MEN1 4323/4885KMT2A 1017/4885 |
| US-20260146064-A1 | PH-SENSITIVE MEMBRANE DISRUPTIVE PEPTIDES AND USE THEREOF | LNPK, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, YWHAZ | TOP2A 3011/4885MEN1 592/4885KMT2A 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.